Flexoject en es it fr

Flexoject Brand names, Flexoject Analogs

Flexoject Brand Names Mixture

  • No information avaliable

Flexoject Chemical_Formula


Flexoject RX_link


Flexoject fda sheet

Flexoject FDA

Flexoject msds (material safety sheet)

Flexoject MSDS

Flexoject Synthesis Reference

No information avaliable

Flexoject Molecular Weight

269.381 g/mol

Flexoject Melting Point

156-157 oC

Flexoject H2O Solubility

Sparingly soluble in water

Flexoject State


Flexoject LogP


Flexoject Dosage Forms

Tablet (extended-release)

Flexoject Indication

Indicated for the treatment of Parkinson's disease.

Flexoject Pharmacology

Orphenadrine is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. Orphenadrine is an anticholinergic with a predominantly central effect and only a weak peripheral effect. In addition, it has mild antihistaminic and local anaesthetic properties. Parkinson's syndrome is the consequence of a disturbed balance between cholinergic and dopaminergic neurotransmission in the basal ganglia caused by a decrease in dopamine. Orphenadrine restores the physiological equilibrium and has a favourable effect on the rigidity and tremor of Parkinson's disease and Parkinsonian syndromes. The effect is somewhat less on bradykinesia.

Flexoject Absorption

Orphenadrine is almost completely absorbed in the gastrointestinal tract.

Flexoject side effects and Toxicity

Oral, mouse LD50 = 100 mg/kg; oral, rat LD50 = 255 mg/kg

Flexoject Patient Information

No information avaliable

Flexoject Organisms Affected

Humans and other mammals